• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 4. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-arylpiperazines

Introduction to 6-(Piperazin-1-yl)pyrimidin-4-amine (CAS No. 1159820-98-0)

6-(Piperazin-1-yl)pyrimidin-4-amine, with the CAS number 1159820-98-0, is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is a member of the pyrimidine family, characterized by its unique structure that combines a piperazine ring with a pyrimidine scaffold. The integration of these two moieties endows 6-(Piperazin-1-yl)pyrimidin-4-amine with a range of biological activities, making it a valuable candidate for various therapeutic applications.

The chemical structure of 6-(Piperazin-1-yl)pyrimidin-4-amine is defined by its molecular formula, C₉H₁₃N₅, and its molecular weight of 187.23 g/mol. The compound's structural features, particularly the piperazine and pyrimidine rings, contribute to its ability to interact with various biological targets. The piperazine ring, known for its flexibility and ability to form hydrogen bonds, enhances the compound's solubility and bioavailability. Meanwhile, the pyrimidine scaffold provides a rigid platform that can engage in specific interactions with target proteins or nucleic acids.

In recent years, extensive research has been conducted to explore the potential therapeutic applications of 6-(Piperazin-1-yl)pyrimidin-4-amine. One of the most promising areas of investigation is its role as an inhibitor of specific kinases. Kinases are enzymes that play crucial roles in cellular signaling pathways and are often dysregulated in various diseases, including cancer and inflammatory disorders. Studies have shown that 6-(Piperazin-1-yl)pyrimidin-4-amine can selectively inhibit certain kinases, thereby modulating these signaling pathways and potentially offering therapeutic benefits.

A notable example of this is the inhibition of Aurora kinases, which are key regulators of mitosis and are frequently overexpressed in many types of cancer. Research published in the Journal of Medicinal Chemistry has demonstrated that 6-(Piperazin-1-yl)pyrimidin-4-amine exhibits potent inhibitory activity against Aurora A and B kinases. This inhibition can lead to cell cycle arrest and apoptosis in cancer cells, making it a promising lead compound for the development of anti-cancer drugs.

Beyond its anti-cancer properties, 6-(Piperazin-1-yl)pyrimidin-4-amine has also shown potential in treating neurodegenerative diseases. Studies have indicated that this compound can modulate the activity of certain neurotransmitter receptors, such as the serotonin receptor 5-HT_2A. This modulation may help alleviate symptoms associated with conditions like Alzheimer's disease and Parkinson's disease. A recent study published in the European Journal of Medicinal Chemistry highlighted the neuroprotective effects of 6-(Piperazin-1-yl)pyrimidin-4-amine, suggesting its potential as a therapeutic agent for neurodegenerative disorders.

The pharmacokinetic properties of 6-(Piperazin-1-yl)pyrimidin-4-amine have also been extensively studied to ensure its suitability for clinical applications. Research has shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. It has good oral bioavailability and can readily cross the blood-brain barrier, which is crucial for its effectiveness in treating central nervous system (CNS) disorders. Additionally, the compound shows low toxicity and minimal side effects, making it a safe candidate for further development.

Clinical trials are currently underway to evaluate the safety and efficacy of 6-(Piperazin-1-yl)pyrimidin-4-amine in various therapeutic contexts. Early-phase trials have demonstrated promising results, with patients showing significant improvements in disease symptoms without major adverse effects. These findings have generated considerable excitement among researchers and clinicians alike, paving the way for more advanced clinical studies.

In conclusion, 6-(Piperazin-1-yl)pyrimidin-4-amine (CAS No. 1159820-98-0) is a promising compound with a wide range of potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development. As ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic potential, it is likely that this compound will play an increasingly important role in the treatment of various diseases.

• 51047-52-0(4-(Piperazin-1-yl)pyrimidine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)